Introduction {#Sec1}
============

Acute promyelocytic leukemia (APL) is a distinctive subtype of acute myelocytic leukemia characterized by reciprocal translocations between chromosomes 15 and 17. Many clinical trials have demonstrated that both new and relapsed APL patients can achieve complete remission after arsenic trioxide treatment \[[@CR1]--[@CR7]\]. Generally, APL patients receive intravenous infusions of an aqueous solution of inorganic arsenic over the course of 2--5 h \[[@CR1], [@CR2], [@CR4], [@CR7]\]. In spite of the good efficacy of arsenic treatment, fatalities of APL patients and arsenic-induced side effects, e.g., skin and gastrointestinal reactions, liver and cardiac dysfunction, and neuropathy, have also been reported \[[@CR2], [@CR4], [@CR7]--[@CR9]\]. With the aim of alleviating side effects and maximizing treatment efficacy, extensive efforts have been made to elucidate the mechanisms of action, such as the effects of arsenic on apoptosis, differentiation, degradation of oncogenic fusion proteins, and signal transduction \[[@CR10]--[@CR14]\], as well as metabolism of arsenic in APL patients \[[@CR15]--[@CR17]\].

Inorganic arsenic can be readily transformed in many organisms through a biological process consisting of alternating reduction and oxidative methylation reactions, which consequently leads to the formation of various arsenic metabolites \[[@CR15], [@CR18]--[@CR22]\]. Monomethylarsonic acid (MMA^V^) and dimethylarsinic acid (DMA^V^) have commonly been detected in human urine, saliva, and blood \[[@CR15], [@CR16], [@CR20]--[@CR26]\]. However, monomethylarsonous acid (MMA^III^) and dimethylarsinous acid (DMA^III^), which are proposed as important intermediates in the transformation process of inorganic arsenic, have been detected only in human urine \[[@CR15], [@CR27]--[@CR29]\]. Recently, thiolated methylated arsenicals have also been identified as metabolites of inorganic arsenic in human urine \[[@CR30], [@CR31]\].

Various arsenic metabolites exhibit differing toxicities. For instance, trivalent methylated arsenicals are more toxic than their pentavalent counterparts \[[@CR12], [@CR32]--[@CR35]\], and the toxicities of thiolated arsenicals are greater than those of pentavalent oxygen-containing analogs \[[@CR30], [@CR36]--[@CR38]\]. Owing to the extreme variations in the toxicity of arsenic metabolites, it is necessary to identify and quantify arsenic species in APL patients undergoing arsenic treatment. The speciation information will contribute to improve our understanding of arsenic metabolism and to the design of timely clinical intervention and personalized therapy.

Although previous studies have determined arsenicals in the urine and blood of APL patients undergoing arsenic treatment \[[@CR15]--[@CR17]\], arsenic speciation in the saliva of APL patients has not been reported. Salivary glands have high blood flows, and arsenic species in the blood could be distributed to saliva. Collection of saliva samples is noninvasive and readily achievable. Thus, determination of arsenic species in saliva can complement biomonitoring of arsenic species in urine and blood, serving as a potential biomarker for assessment of recent exposure. The primary objective of this work is to identify and quantify arsenic species in saliva samples from APL patients undergoing arsenic treatment. Achieving this objective involves the development of arsenic speciation analysis and the application of this technique to determining temporal profiles of arsenic species in saliva.

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

MMA^III^ and DMA^III^ were synthesized in the iodide form of CH~3~AsI~2~ and (CH~3~)~2~AsI according to the literature \[[@CR39]\], and were kept at 4 and −20 °C, respectively. Monomethylmonothioarsonic acid (MMMTA^V^) and dimethylmonothioarsinic acid (DMMTA^V^) were prepared according to a reported method \[[@CR40]\], and were stored at −20 °C. Their stock solutions were freshly prepared in deionized water. Stock solutions of other standards (1,000 mg/L as arsenic) were prepared by dissolving appropriate amounts of As^III^, As^V^, DMA^V^ (all from Aldrich), and MMA^V^ (Chem Service) in deionized water. Their working solutions were prepared daily by serial dilutions in deionized water.

Tetrabutylammonium hydroxide (Aldrich), malonic acid (Aldrich), and high-performance liquid chromatography (HPLC) grade methanol (Fisher) were used for preparing the mobile phase. The mobile phase was filtered through a 0.45-μm membrane filter.

A certified reference material ("Toxic Metals in Freeze-Dried Human Urine," certified reference material no. 18 from the National Institute for Environmental Studies, Japan Environment Agency) was used for quality control purposes. This certified reference material was reconstituted by dissolving it in 20.0 mL deionized water according to the instructions provided by the supplier. The certified value for DMA^V^ was 36 ± 9 μg/L.

APL patients and sample collection {#Sec4}
----------------------------------

Saliva samples were collected from nine patients who were undergoing arsenic treatment at Harbin Medical University Hospital. Informed consent was acquired from each patient prior to the study, which was conducted in compliance with the guidelines and regulations of the ethical review boards of the University of Alberta and Harbin Medical University Hospital (200816). Demographic information on the APL patients is given in Table [1](#Tab1){ref-type="table"}. Two relapsed patients were returning for arsenic treatment, and the other patients were newly diagnosed with APL. Before the start of sample collection, two patients (one returning and one new) did not receive arsenic treatment, whereas the other patients had been treated with arsenic for differing durations, as shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic information on acute promyelocytic leukemia (APL) patients who participated in this studyPatient IDGenderAge (years)New or relapsedDuration of arsenic treatment (days)1F29Relapsed02F36Relapsed43F19New544F24New05F24New136M30New117F40New98M50New449F52New16*F* female, *M* male

Ten milligrams of As~2~O~3~ (Yida Pharmaceutical, Harbin, China) dissolved in a 10-mL aqueous solution was added to 500 mL of 5 % glucose normal saline solution for intravenous infusion. The infusion usually takes 2--4 h. Arsenic was administered to patients 4, 5, and 9 over a period as long as 18 h because it caused them serious side effects. White blood cell counts and routine blood analysis were performed to monitor the health of APL patients. One saliva sample was collected from each patient immediately prior to daily infusion of arsenic. All patients then received intravenous infusions of the same dose of As^III^ (10 mg As~2~O~3~), and saliva samples were collected consecutively in the subsequent 24 h before the next infusion. Sample collection was repeated for two or three 24-h cycles following different As^III^ infusions. In total, 108 saliva samples were collected from nine APL patients. APL patients were required to rinse their mouths thoroughly with deionized water three times before saliva sampling; then they spat saliva samples directly into 15-mL polyethylene centrifuge tubes. Immediately after sample collection, saliva samples were divided into three 1-mL aliquots in 1.5-mL vials. The vials were sealed with Parafilm and transported on dry ice. The samples were stored at −20 °C until arsenic speciation analysis.

Pretreatment of saliva for arsenic speciation analysis {#Sec5}
------------------------------------------------------

The method of pretreatment of saliva for arsenic speciation analysis has been described in the literature \[[@CR23]\]. In brief, frozen saliva samples were thawed at room temperature and thoroughly vortex-mixed. A 0.5-mL aliquot of saliva samples was diluted three times with deionized water in a 15-mL centrifuge tube, and thoroughly vortex-mixed again. The diluted saliva samples were sonicated for 30 min, and then filtered through a 0.45-μm membrane filter prior to arsenic speciation analysis.

Identification and quantification of arsenic species by HPLC--inductively coupled plasma mass spectrometry {#Sec6}
----------------------------------------------------------------------------------------------------------

An Agilent 1100 series HPLC system consisting of a pump, degasser, autosampler, column temperature control, and reversed-phase C~18~ column (ODS-3, 150 mm × 4.6 mm, 3-μm particle size; Phenomenex, Torrance, CA, USA) was used for the separation of arsenicals. An octadecylsilane guard cartridge (4 mm × 3 mm) was mounted before the analytical column. The mobile phase consisted of 5 mM tetrabutylammonium, 5 % methanol, and 3 mM malonic acid (pH 5.65). The column was equilibrated with the mobile phase for at least 0.5 h at a flow rate of 0.8 mL/min before sample injection. A 50-μL aliquot of pretreated saliva samples was injected and separation was performed at a flow rate of 1.2 mL/min; the column temperature was maintained at 50 °C.

The effluent from HPLC was introduced directly into the nebulizer of a 7500ce inductively coupled plasma (ICP) mass spectrometry (MS) instrument (Agilent Technologies, Japan) using PEEK tubing. The collision cell of the ICP MS instrument was operated in helium mode. Helium (3.5 mL/min) was used in the octopole reaction cell to reduce isobaric and polyatomic interferences. The ICP operated at a radio-frequency power of 1,550 W, and the flow rate of argon carrier gas was 0.9--1.0 L/min. Arsenic was monitored at *m*/*z* 75. Chromatograms from HPLC separation were recorded by ICP-MS ChemStation (Agilent Technologies, Santa Clara, CA, USA).

Identification of MMMTA^V^ by HPLC--electrospray ionization tandem mass spectrometry {#Sec7}
------------------------------------------------------------------------------------

For optimization of operating conditions, 1--5 μM MMMTA^V^ in a solution of methanol and water (1:1, v/v) was infused into a triple-quadrupole mass spectrometer (5000 QTRAP, MDS SCIEX, Concord, ON, Canada) equipped with an electrospray ion source. The electrospray ionization (ESI) tandem mass spectrometry (MS/MS) instrument was operated in negative ionization mode. The characteristic multiple reaction monitoring transitions of MMMTA^V^ were 155/107, 155/121, and 155/137. The optimal parameters were as follows: IonSpray voltage −4,500 V, interface temperature 200 °C, curtain gas flow rate 10 L/min, and declustering potential −75 V. The collision energy and the cell exit potential were −34 and −13 V for 155/107, -22 and −11 V for 155/121, and −22 and −11 V for 155/137.

The ESI-MS/MS instrument was coupled with an 1100 series HPLC system (Agilent, Santa Clara, CA, USA) equipped with a quaternary pump, degasser, column temperature control, and temperature-controlled autosampler. An anion-exchange column (PRP-X100, 50 mm × 4.6 mm, 10 μm; Hamilton, Reno, NV, USA) was used for separation, with the mobile phase comprising 50 % methanol and 5 mM ammonium formate (pH 6) at a flow rate of 1 mL/min. The temperature of the autosampler was kept at 4 °C, and the injection volume was 50 μL.

Results {#Sec8}
=======

Trivalent and thiolated monomethylated arsenicals, MMA^III^ and MMMTA^V^ {#Sec9}
------------------------------------------------------------------------

Separation of eight arsenicals---As^III^, MMA^III^, DMA^V^, MMA^V^, As^V^, DMMTA^V^, DMA^III^, and MMMTA^V^---was achieved using ion-pair chromatography, as shown in Fig. [1](#Fig1){ref-type="fig"}, chromatogram A. A typical chromatogram of saliva samples from APL patients undergoing arsenic treatment is shown in Fig. [1](#Fig1){ref-type="fig"}, chromatogram B. These results demonstrated that As^III^, MMA^III^, DMA^V^, MMA^V^, As^V,^ and MMMTA^V^ were detectable in the saliva of APL patients. The presence of MMA^III^ and MMMTA^V^ in human saliva has not been reported in previous studies.Fig. 1Typical chromatograms of arsenic standards (*A*) and saliva samples (*B*) from acute promyelocytic leukemia (APL) patients. Separation was achieved using a reversed-phase ODS-3 column, and a mobile phase comprising 5 mM tetrabutylammonium, 3 mM malonic acid, and 5 % methanol (pH 5.65). Arsenic was detected at *m*/*z* 75 using an Agilent 7500ce inductively coupled plasma mass spectrometry (ICPMS) instrument with an octopole reaction system. Peaks *1*--*8* correspond to As^III^, monomethylarsonous acid (MMA^III^), dimethylarsinic acid (DMA^V^), monomethylarsonic acid (MMA^V^), dimethylmonothioarsonic acid, dimethylarsinous acid (DMA^III^), As^V^, and monomethylmonothioarsonic acid (MMMTA^V^), respectively

To confirm the presence of MMA^III^ and MMMTA^V^ in the saliva of APL patients, we analyzed the saliva samples spiked with authentic standards of MMA^III^ or MMMTA^V^. Figure [2](#Fig2){ref-type="fig"} shows a comparison of the chromatograms of the original sample and the same sample spiked with authentic standards. The spiked MMA^III^ or MMMTA^V^ standard was co-eluted with suspected compounds, giving rise to a distinct increase in the intensity of peak corresponding to MMA^III^ or MMMTA^V^. The MMMTA^V^ and MMA^III^ standards are not stable. MMMTA^V^ can decompose easily into MMA^III^, and thereafter MMA^III^ can be oxidized to MMA^V^. Even when stored at −80 °C after synthesis, MMMTA^V^ still can produce some MMA^III^ and MMA^V^ during the thawing process. Thus, spiking of MMMTA^V^ also increased the intensities of the peaks of MMA^III^ and MMA^V^ (Fig. [2](#Fig2){ref-type="fig"}, chromatograms B). Because MMA^III^, MMA^V^, and MMMTA^V^ were well resolved in the chromatogram, these spiking experiments could still demonstrate the existence of MMA^III^ and MMMTA^V^ in the saliva of APL patients. The chromatographic fraction containing MMA^III^ was also collected and treated with hydrogen peroxide (H~2~O~2~) to render the oxidation of MMA^III^ to MMA^V^. As demonstrated in Fig. [3](#Fig3){ref-type="fig"}, detection of MMA^V^ in an H~2~O~2~-pretreated MMA^III^-containing chromatographic fraction provided further evidence that MMA^III^ was present in the saliva of APL patients.Fig. 2Chromatograms of saliva samples and the same samples spiked with authentic arsenic standards. Peak identities and high-performance liquid chromatography (HPLC)--ICPMS conditions were the same as those for Fig. [1](#Fig1){ref-type="fig"}. *A* chromatograms were obtained from a saliva sample (solid trace) and the same sample spiked with authentic MMA^III^ (*dashed trace*). *B* chromatograms were obtained from a saliva sample (*solid trace*) and the same sample spiked with MMMTA^V^ (*dashed trace*)Fig. 3A chromatogram obtained from HPLC--ICPMS analysis of an H~2~O~2~-treated chromatographic fraction containing MMA^III^. Peak identities and HPLC--ICPMS conditions are the same as those for Fig. [1](#Fig1){ref-type="fig"}

ESI-MS/MS can provide information on the chemical structures of the compounds; therefore, an HPLC-ESI-MS/MS method was developed for the identification of MMMTA^V^. Unfortunately, the concentration of MMMTA^V^ in the saliva of APL patients was below the detection limit of ESI-MS/MS. Nevertheless, the authenticity of the synthesized MMMTA^V^ standard used was confirmed using the ESI-MS/MS method. As shown in Fig. [4](#Fig4){ref-type="fig"}, the peaks representing characteristic ion transitions of MMMTA^V^ (155/107, 155/121, and 155/137) were superimposed, which demonstrated the authenticity of the MMMTA^V^ standard synthesized in our laboratory.Fig. 4Chromatogram obtained from HPLC--electrospray ionization tandem mass spectrometry (ESI-MS/MS) analysis of synthesized MMMTA^V^ standard. Anion-exchange separation was performed using a Hamilton PRP-X100 column and a mobile phase comprising 50 % methanol and 5 mM ammonium formate (pH 6). ESI-MS/MS was performed in multiple reaction monitoring mode. Three characteristic ion transitions, 155/107, 155/121, and 155/137, of MMMTA^V^ were monitored simultaneously

The results for MMA^III^ and MMMTA^V^ in the saliva of APL patients are summarized in Table [2](#Tab2){ref-type="table"}. MMA^III^ and MMMTA^V^ were detected in 49 % and 22 % of saliva samples from APL patients, respectively. The mean concentration of MMA^III^ in all detectable saliva samples was 1.4 ng/mL, and the mean concentration of MMMTA^V^ was 3.6 ng/mL. MMA^III^ and MMMTA^V^ accounted for 2.2 % and 4.0 % of total arsenic in the saliva of APL patients, respectively. Table [3](#Tab3){ref-type="table"} shows the concentrations of MMA^III^ and MMMTA^V^ in the saliva of each of the APL patients. MMA^III^ was detected in saliva samples from each of the APL patients. However, MMMTA^V^ was only found in the saliva of patients 3, 7, and 8. The mean concentrations of MMA^III^ and MMMTA^V^ differed among the APL patients. The saliva of patient 8 contained the highest concentrations of MMA^III^ (1.9 ± 0.6 ng/mL) and MMMTA^V^ (5.3 ± 2.9 ng/mL) among all patients.Table 2Summary of arsenic species in saliva samples collected from APL patientsArsenic species in saliva sampleMean concentration (ng/mL)Detectable range (ng/mL)Number of detectable samplesPercentage of detectable samplesPercent concentration over sum of all speciesMeanRangeAs^III^39.10.3--181.51069872.40--100As^V^9.2ND to 84.61069818.70--72.0DMA^V^1.0ND to 5.2106983.00--34.7MMA^V^2.0ND to 7.3106984.80--17.9MMA^III^1.4ND to 4.853492.20--4.1MMMTA^V^3.6ND to 10.624224.00--9.2Sum of all species52.20.1--210.1*ND* not detectable, *DMA*^*V*^ dimethylarsinic acid, *MMA*^*V*^ monomethylarsonic acid, *MMA*^*III*^ monomethylarsonous acid, *MMMTA*^*V*^ monomethylmonothioarsonic acidTable 3Summary of arsenic species in saliva samples from individual APL patientsBefore or after the first arsenic infusionID of APL patientNumber of samplesConcentrations of arsenic species (ng/mL) \[mean ± SD (*n*)\]As^III^DMA^V^MMA^V^As^V^MMA^III^MMMTA^V^Before110.3NDNDNDNDND41ND0.1ND0.1NDNDAfter11812.1 ± 9.00.7 ± 0.51.3 ± 0.93.7 ± 3.10.6 ± 0.2 (2)ND2957.4 ± 17.71.3 ± 0.54.3 ± 2.05.1 ± 1.81.3 ± 0.3 (9)ND3759.1 ± 23.20.5 ± 0.12.3 ±0.613.9 ± 9.01.6 ± 0.5 (4)2.9 ± 1.6 (7)4920.1 ± 25.10.6 ± 0.40.9 ± 0.62.8 ± 2.20.7 ± 0.6 (6)ND52027.0 ± 11.30.7 ± 0.31.7 ± 0.813.8 ± 9.80.4 ± 0.1 (3)ND61635.5 ± 17.01.8 ± 1.01.8 ± 1.13.2 ± 2.51.3 ± 0.7 (14)ND7696.9 ± 46.31.2 ± 0.61.4 ± 0.76.3 ± 5.42.7 ± 1.5 (4)1.0 ± 0.5 (5)81164.7 ± 20.10.9 ± 0.22.9 ± 1.215.7 ± 7.41.9 ± 0.6 (10)5.3 ± 2.9 (11)91045.2 ± 18.91.7 ± 1.42.1 ± 1.321.4 ± 22.90.8 (1)1.6 (1)*ND* not detectable, *SD* standard deviation, *n* number of samples in which MMA^III^ and MMMTA^V^ were detected

As^III^, DMA^V^, MMA^V^, and As^V^ {#Sec10}
----------------------------------

The results for As^III^, DMA^V^, MMA^V^, and As^V^ in saliva samples from APL patients are also shown in Table [2](#Tab2){ref-type="table"}. As^III^, DMA^V^, MMA^V^, and As^V^ were detectable in 98 % of saliva samples. The mean concentration was 39.1 ng/mL for As^III^, 9.2 ng/mL for As^V^, 1.0 ng/mL for DMA^V^, and 2.0 ng/mL for MMA^V^. The summed concentration of all arsenicals in the saliva ranged from 0.1 to 210.1 ng/mL, with a mean concentration of 52.2 ng/mL. As^III^ was the predominant species in the saliva of APL patients, and accounted for 71.8 % of arsenic in the saliva.

The arsenic concentration was low in two saliva samples collected from patients 1 and 4 before the first arsenic injection (Table [3](#Tab3){ref-type="table"}). The saliva of patient 1 contained only 0.3 ng/mL As^III^, and the saliva of patient 4 contained 0.1 ng/mL DMA^V^ and 0.1 ng/mL As^V^. The rest of the saliva samples were collected after the first infusion of arsenic, and the concentrations of arsenic were much higher than in the samples collected before any infusion of arsenic. As^III^, DMA^V^, MMA^V^, and As^V^ were detected in all saliva samples collected after the first infusion of arsenic, and As^III^ was consistently the predominant arsenic species in the saliva of all patients. Although the same dose of arsenic trioxide was administered to all APL patients, the mean concentrations of arsenicals differed among individual APL patients. Patients 2, 3, 7, and 8 had higher concentrations of arsenic in the saliva compared with the other patients.

Temporal profiles of common arsenic species {#Sec11}
-------------------------------------------

Figure [5](#Fig5){ref-type="fig"} shows the temporal profiles of four common arsenic species (As^III^, DMA^V^, MMA^V^, and As^V^) and their sum in the saliva of patients 4 and 6. Before the study, patient 4 did not receive an arsenic injection, but arsenic was administered to patient 6 (relapsed) for 11 days. Saliva samples were consecutively collected for 72 h from patient 4 (Fig. [5a](#Fig5){ref-type="fig"}) and for 52 h from patient 6 (Fig. [5b](#Fig5){ref-type="fig"}). Three infusions of arsenic were administered to patient 4 during the sample collection period, and two infusions were administered to patient 6. The interval between arsenic infusions was 24 h. As shown in Fig. [5a](#Fig5){ref-type="fig"}, the arsenic concentration was low in the saliva sample of patient 4 before arsenic infusion. Following the first arsenic infusion, the concentrations of arsenicals in the saliva increased immediately, and decreased thereafter. The profiles were similar following the second and third infusions. Nevertheless, the overall level of arsenic in the saliva increased with the progression of arsenic treatment, indicating that arsenic had accumulated in the body of patient 4. Compared with patient 4, the background arsenic concentration in the first saliva sample of patient 6 (Fig. [5b](#Fig5){ref-type="fig"}) was higher because arsenic trioxide had been administered to this patient 11 times over 11 days prior to the study. The arsenic concentration in the saliva of patient 6 showed a delayed increase in response to arsenic infusion, and similar patterns of changes in the two subsequent monitoring cycles.Fig. 5Temporal profiles showing the concentrations of arsenic species in the saliva of APL patients. The patients received an intravenous infusion of a 10 mg dose of arsenic trioxide daily. The *arrows* indicate the time at which the infusion started. Collection of saliva samples from patient 4 (**a**) lasted 72 h with three arsenic (As^III^) administrations of long infusion duration (about 18 h), and saliva samples from patient 6 (**b**) were collected for 52 h with two administrations of short infusion duration (below 4 h). *Squares* As^III^, *circles* DMA^V^, *upright triangles* MMA^V^, inverted *triangles* As^V^, *diamonds* sum of arsenic species

Temporal profiles of percentages of methylated arsenicals in the saliva of patients 4 and 6 are presented in Fig. [6](#Fig6){ref-type="fig"}. Following arsenic infusion, the percentages of MMA^V^, DMA^V^, and their sum decreased in the saliva of both patients, suggesting that the methylation efficiency of As^III^ was inhibited by accumulating As^III^. However, there was a difference in the temporal profiles of the percentages of salivary arsenicals between patients 4 and 6. The percentage of methylated arsenicals in the saliva of patient 4 declined continuously from 35 % to 6 %, as shown in Fig. [6a](#Fig6){ref-type="fig"}. For patient 6, the percentages of methylated arsenicals decreased immediately following arsenic infusion, and increased thereafter (Fig. [6b](#Fig6){ref-type="fig"}). A comparably similar profile between the two patients was repeated only after the second infusion.Fig. 6Temporal profiles showing the percentages of methylated arsenicals in the saliva of APL patient 4 (**a**) and patient 6 (**b**). The procedures for arsenic administration were the same as described for Fig. [5](#Fig5){ref-type="fig"}. *Triangles* MMA^V^, *circles* DMA^V^, *diamonds* sum of methylated arsenic

Discussion {#Sec12}
==========

Following arsenic trioxide administration, a portion of As^III^ can be transformed into methylated arsenicals in the body of APL patients through the processes of biological methylation \[[@CR19], [@CR41]\]. Salivary glands have high blood flow, and chemicals and their metabolites in blood can be distributed in saliva through passive diffusion, active transport, and ultrafiltration \[[@CR42]--[@CR45]\]. Our previous efforts showed that As^III^ and its metabolites are present in saliva in populations who were chronically exposed to arsenic via drinking water or from chromated copper arsenate treated wood in playgrounds \[[@CR23]--[@CR25]\]. No attention has been paid to arsenic speciation in human saliva in clinical settings, in which APL patients were acutely exposed to high doses of As^III^ via intravenous infusion.

Most arsenic in the saliva of APL patients was detected as As^III^. MMA^V^ and DMA^V^, metabolites of As^III^ commonly found in human urine \[[@CR15], [@CR16], [@CR20]--[@CR26]\], were also detected in saliva of APL patients. As important intermediates in the transformation processes of As^III^, MMA^III^ and DMA^III^ were found in human urine in previous studies \[[@CR15], [@CR27]--[@CR29]\]. Our present study demonstrates the presence of MMA^III^ in the saliva of APL patients who received a high dose of As^III^, which provides additional evidence of biomethylation of As^III^ in the human body. The cytotoxicity and genotoxicity of MMA^III^ were shown to be greater than those of inorganic arsenic and pentavalent methylated arsenicals \[[@CR12], [@CR32]--[@CR35]\]

Thiolated methylated arsenicals have recently been identified as arsenic metabolites in human urine and nails \[[@CR30], [@CR31]\]. The present study also shows the presence of MMMTA^V^ in the saliva of APL patients (patients 3, 7, and 8) undergoing arsenic treatment. Little is known about how these thiolated metabolites of arsenic are produced in the human body. Previous studies demonstrated that thiolated arsenicals may be produced in the gastrointestinal tract of rats by intestinal flora \[[@CR46], [@CR47]\]. However, in our study arsenic was administered to APL patients via intravenous infusion, and it was unlikely that MMMTA^V^ in the saliva of APL patients was produced in the gastrointestinal tract. Thiolated arsenicals could probably be formed using H~2~S produced from enzymatically catalyzed reactions in mammalian cells \[[@CR48], [@CR49]\]. Thiolated methylated arsenicals were shown to be more toxic than their oxygen-containing analogs and exhibited toxicity comparable to that of trivalent arsenicals \[[@CR30], [@CR36]--[@CR38]\].

Most arsenic infused is excreted from the bodies of APL patients through urine \[[@CR15], [@CR50]\]. The temporal profiles of salivary arsenicals depicted in our present study might well indicate the overall process of arsenic infusion, metabolism, and tributary excretion from the body. Arsenic accumulated in the saliva of patient 4 in the initial stage of treatment, but in the saliva of patient 6 the arsenic concentration reached a steady state after the adaptation to arsenic treatment. Likewise, a steady state was also reached in the urine within 5 days after repeated ingestion of 125--1,000 μg As^III^ daily \[[@CR50]\].

Many efforts have been made to understand whether high doses of ingested As^III^ can affect methylation of arsenic in the living body. It was demonstrated that the formation of DMA^V^ could be effectively inhibited by heavy ingestion of As^III^ \[[@CR51], [@CR52]\]. Compared with the general population, APL patients who received high doses of As^III^ intravenously had a lower fraction of DMA^V^ in their urine \[[@CR15]\], an observation that was supported by the saliva analysis in the present study. Methylated arsenicals accounted for 24 % of arsenic in the saliva of a general population chronically exposed to arsenic in drinking water \[[@CR23]\]. In contrast, the percentage of methylated arsenicals in the saliva of APL patients was only 7.8 %. Additionally, the percentage of methylated arsenicals in the saliva of APL patients significantly decreased following each As^III^ infusion, reflecting possible saturation of arsenic methylation by the high levels of As^III^ in the body of APL patients.
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